JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Allogene Therapeutics Inc

Закрыт

СекторЗдравоохранение

2.38 1.71

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2.3

Макс.

2.49

Ключевые показатели

By Trading Economics

Доход

2.6M

-39M

Сотрудники

150

EBITDA

-1.4M

-39M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+275.43% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

12 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

271M

832M

Предыдущая цена открытия

0.67

Предыдущая цена закрытия

2.38

Новостные настроения

By Acuity

50%

50%

179 / 348 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Allogene Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

23 апр. 2026 г., 00:00 UTC

Главные новостные события

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 апр. 2026 г., 23:33 UTC

Отчет

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 апр. 2026 г., 22:40 UTC

Отчет

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 апр. 2026 г., 22:10 UTC

Приобретения, слияния, поглощения

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 апр. 2026 г., 21:11 UTC

Отчет

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 апр. 2026 г., 21:01 UTC

Отчет

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 апр. 2026 г., 23:46 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

22 апр. 2026 г., 23:46 UTC

Обсуждения рынка

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 апр. 2026 г., 23:34 UTC

Обсуждения рынка
Главные новостные события

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 апр. 2026 г., 23:16 UTC

Отчет

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 апр. 2026 г., 23:15 UTC

Отчет

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 апр. 2026 г., 22:54 UTC

Отчет

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 апр. 2026 г., 22:54 UTC

Отчет

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 апр. 2026 г., 22:52 UTC

Отчет

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 апр. 2026 г., 22:51 UTC

Отчет

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 апр. 2026 г., 22:31 UTC

Отчет

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 апр. 2026 г., 22:31 UTC

Отчет

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 апр. 2026 г., 22:30 UTC

Отчет

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 апр. 2026 г., 22:30 UTC

Отчет

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 апр. 2026 г., 22:29 UTC

Отчет

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 апр. 2026 г., 22:28 UTC

Отчет

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 апр. 2026 г., 22:28 UTC

Отчет

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 апр. 2026 г., 22:27 UTC

Отчет

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 апр. 2026 г., 22:06 UTC

Обсуждения рынка
Отчет

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 апр. 2026 г., 21:55 UTC

Приобретения, слияния, поглощения

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 апр. 2026 г., 21:47 UTC

Отчет

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 апр. 2026 г., 21:37 UTC

Отчет

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 апр. 2026 г., 21:34 UTC

Отчет

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 апр. 2026 г., 21:29 UTC

Отчет

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 апр. 2026 г., 21:20 UTC

Обсуждения рынка
Отчет

Tesla Expands Manufacturing to Chips -- Market Talk

Сравнение c конкурентами

Изменение цены

Allogene Therapeutics Inc Прогноз

Целевая цена

By TipRanks

275.43% рост

Прогноз на 12 месяцев

Средняя 8.71 USD  275.43%

Максимум 14 USD

Минимум 3.85 USD

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Allogene Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

14 ratings

12

Покупка

2

Удержание

0

Продажа

Техническая оценка

By Trading Central

1.18 / 1.69Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

179 / 348Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat